Literature DB >> 30523122

DUO delivers for duvelisib.

Jennifer R Brown1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30523122      PMCID： PMC6284219          DOI： 10.1182/blood-2018-10-879650

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Authors:  Benjamin L Lampson; Siddha N Kasar; Tiago R Matos; Elizabeth A Morgan; Laura Rassenti; Matthew S Davids; David C Fisher; Arnold S Freedman; Caron A Jacobson; Philippe Armand; Jeremy S Abramson; Jon E Arnason; Thomas J Kipps; Joshua Fein; Stacey Fernandes; John Hanna; Jerome Ritz; Haesook T Kim; Jennifer R Brown
Journal:  Blood       Date:  2016-05-31       Impact factor: 22.113

2.  Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Authors:  Susan O'Brien; Manish Patel; Brad S Kahl; Steven M Horwitz; Francine M Foss; Pierluigi Porcu; Jeffrey Jones; Jan Burger; Nitin Jain; Kerstin Allen; Kerrie Faia; Mark Douglas; Howard M Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Ian Flinn
Journal:  Am J Hematol       Date:  2018-10-20       Impact factor: 10.047

3.  Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Authors:  Jeffrey A Jones; Tadeusz Robak; Jennifer R Brown; Farrukh T Awan; Xavier Badoux; Steven Coutre; Javier Loscertales; Kerry Taylor; Elisabeth Vandenberghe; Malgorzata Wach; Nina Wagner-Johnston; Loic Ysebaert; Lyndah Dreiling; Ronald Dubowy; Guan Xing; Ian W Flinn; Carolyn Owen
Journal:  Lancet Haematol       Date:  2017-03       Impact factor: 18.959

4.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113

5.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Authors:  Martin Dreyling; Armando Santoro; Luigina Mollica; Sirpa Leppä; George A Follows; Georg Lenz; Won Seog Kim; Arnon Nagler; Panayiotis Panayiotidis; Judit Demeter; Muhit Özcan; Marina Kosinova; Krimo Bouabdallah; Franck Morschhauser; Don A Stevens; David Trevarthen; Marius Giurescu; Lisa Cupit; Li Liu; Karl Köchert; Henrik Seidel; Carol Peña; Shuxin Yin; Florian Hiemeyer; Jose Garcia-Vargas; Barrett H Childs; Pier Luigi Zinzani
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

6.  PI3Kγ is a molecular switch that controls immune suppression.

Authors:  Megan M Kaneda; Karen S Messer; Natacha Ralainirina; Hongying Li; Christopher J Leem; Sara Gorjestani; Gyunghwi Woo; Abraham V Nguyen; Camila C Figueiredo; Philippe Foubert; Michael C Schmid; Melissa Pink; David G Winkler; Matthew Rausch; Vito J Palombella; Jeffery Kutok; Karen McGovern; Kelly A Frazer; Xuefeng Wu; Michael Karin; Roman Sasik; Ezra E W Cohen; Judith A Varner
Journal:  Nature       Date:  2016-09-19       Impact factor: 49.962
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.